Eli Lilly Zepbound Success - Search News

Order byBest matchMost fresh

News

People lost more weight on Zepbound

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

Continue reading

· 3d · on MSN

FOX 5 Atlanta · 3d

Zepbound vs. Wegovy: Here's which weight loss drug worked best in first trial

· 3d · on MSN

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Zacks Investment Research on MSN1d

Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...

12d

Eli Lilly: Don't Overthink This Buying Opportunity

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

8d

Beyond Valuation Ratios: 3 Undervalued Stocks To Buy In May 2025

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

4d

Wellness companies eager to avoid WeightWatchers’ fate embrace weight-loss drugs

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

24/7 Wall St.3d

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (May 2025)

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results